← Back to Clinical Trials
Recruiting NCT05339568

NCT05339568 Patient's Whole Process Follow-up Management(HOPE-1)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05339568
Status Recruiting
Phase
Sponsor Qianfoshan Hospital
Condition Locally Advanced Non-Small Cell Lung Cancer
Study Type OBSERVATIONAL
Enrollment 1,268 participants
Start Date 2022-05-22
Primary Completion 2030-04-21

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Patients' whole process follow-up and management platform

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,268 participants in total. It began in 2022-05-22 with a primary completion date of 2030-04-21.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.

Eligibility Criteria

Inclusion Criteria: 1. Fully understand the research and voluntarily sign the informed consent form (ICF) 2. Male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form. 3. The subject is diagnosed pathologically or cytologically with non-small cell lung cancer(NSCLC). 4. According to the 8th edition of the American Joint Committee on Cancer \[AJCC\], it is classified as stage IIB, stage III, stage IV NSCLC. 5. Not suitable for radical treatment or refuse surgery. 6. The life expectancy is not less than 3 months. 7. Be able to use a smartphone. Exclusion Criteria: 1. Patients with mental illness. 2. Presence of any other malignant tumor. 3. Patients who are expected to undergo radical surgery. 4. Currently participating in clinical trials. 5. Subjects who judged by the investigator to be unsuitable to participate in the trial.

Contact & Investigator

Central Contact

Jiandong ZHANG

✉ zhangjd165@sina.com

📞 (+86531)89268118

Principal Investigator

Jiandong ZHANG

PRINCIPAL INVESTIGATOR

Shandong First Medical University

Frequently Asked Questions

Who can join the NCT05339568 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Locally Advanced Non-Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05339568 currently recruiting?

Yes, NCT05339568 is actively recruiting participants. Contact the research team at zhangjd165@sina.com for enrollment information.

Where is the NCT05339568 trial being conducted?

This trial is being conducted at Jinan, China.

Who is sponsoring the NCT05339568 clinical trial?

NCT05339568 is sponsored by Qianfoshan Hospital. The principal investigator is Jiandong ZHANG at Shandong First Medical University. The trial plans to enroll 1,268 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology